PepScribe
Transitional · Educational only

Ipamorelin: what the research says. | Reddit

More: Clinical standards · Pharmacy partners · Is PepScribe legit?

A pentapeptide ghrelin-receptor agonist developed by Novo Nordisk in the late 1990s, studied for its ability to stimulate pulsatile growth hormone release with a notably cleaner endocrine profile than older growth-hormone-releasing peptides. Here is what the evidence supports, and where the regulatory and clinical boundaries sit today.

Regulatory notice: Ipamorelin is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List. FDA’s Pharmacy Compounding Advisory Committee reviewed a separate group of peptides for the list on July 23–24, 2026; Ipamorelin was not among them.

This page is educational and is not medical advice. Whether any therapy is appropriate is a clinical decision — talk to a PepScribe clinician to discuss your situation and options.

What Ipamorelin is.

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was first described by Raun and colleagues at Novo Nordisk in a 1998 paper in the European Journal of Endocrinology (Raun et al., 1998), where it was characterized as a potent and selective agonist at the growth hormone secretagogue receptor (GHS-R1a), which is the receptor for the gut-derived hormone ghrelin. Like ghrelin and the older synthetic growth-hormone-releasing peptides (GHRP-2, GHRP-6, hexarelin), ipamorelin stimulates a pulsatile release of growth hormone (GH) from somatotrope cells in the anterior pituitary.

The structural design used non-natural amino acids (alpha-aminoisobutyric acid at the N-terminus, D-2-naphthylalanine and D-phenylalanine in the core) to confer enzymatic stability and high receptor affinity in a short peptide backbone. Ipamorelin sits within the broader class known as GH secretagogues, molecules that elicit GH release through a pathway distinct from growth-hormone-releasing hormone (GHRH).

How it works (proposed mechanisms).

GHS-R1a agonism

Ghrelin receptor activation

Raun et al. (1998) demonstrated that ipamorelin binds GHS-R1a, the endogenous ghrelin receptor, with nanomolar affinity. Receptor binding triggers a Gq-coupled signaling cascade in pituitary somatotropes, including phospholipase C activation, IP3 generation, and intracellular calcium release, which drives GH exocytosis. The result is a pulsatile release of GH that mimics the physiologic ghrelin signal, rather than the sustained elevation that exogenous recombinant GH produces.

Selectivity profile

GH-selective stimulation

The defining pharmacologic feature of ipamorelin, established in the original Raun et al. (1998) work and reinforced by subsequent comparative studies, is its selectivity. Unlike GHRP-2, GHRP-6, and hexarelin, which produce measurable elevations in cortisol, ACTH, and prolactin, ipamorelin at therapeutic doses stimulates GH release without significant activation of the hypothalamic-pituitary-adrenal axis or the lactotrope axis. This cleaner profile is the reason ipamorelin remains the preferred GHRP in most clinician-led protocols.

Synergy with GHRH analogs

Two-arm GH amplification

GH release is regulated by two complementary stimulatory inputs: ghrelin acting at GHS-R1a, and growth-hormone-releasing hormone (GHRH) acting at GHRH-R. Ipamorelin engages the ghrelin arm. CJC-1295 and sermorelin engage the GHRH arm. Combination studies and pharmacology reviews (Sigalos and Pastuszak, 2018, Sexual Medicine Reviews) describe the rationale for combining a GHRH analog with a GHRP: the two pathways converge on the somatotrope without saturating either receptor, producing a larger and more physiologic GH pulse than either agent alone.

Downstream IGF-1

Hepatic IGF-1 generation

GH released from the pituitary acts on hepatocytes via the GH receptor and the JAK2/STAT5 pathway to induce hepatic IGF-1 production. IGF-1 is the primary mediator of many of GH’s peripheral effects on tissue repair, protein synthesis, and body composition. Because ipamorelin works upstream of the pituitary, it preserves the negative-feedback loop, which is the mechanism cited for its endogenous-pulse pharmacology compared with exogenous recombinant GH.

Most pharmacologic data on ipamorelin comes from preclinical work and early-phase human studies. There are no completed Phase 3 trials for any GH indication, and the postoperative-ileus development pathway never reached approval.

Discovery and development history.

Ipamorelin’s development arc tracked a clinical indication that has not, to date, produced an FDA approval.

Novo Nordisk pharmacology (1990s)

Raun et al. (1998, European Journal of Endocrinology) published the foundational pharmacology paper, which described ipamorelin as a GHS-R1a agonist with a unique selectivity profile compared with the older GHRPs in development at the time. The compound was later out-licensed by Novo Nordisk as the company narrowed its endocrine pipeline.

Helsinn postoperative ileus program

Helsinn Therapeutics later developed ipamorelin for postoperative ileus and short-bowel syndrome, conditions in which ghrelin-receptor agonism may promote gastrointestinal motility. Phase 2 trials were conducted, but the program did not progress to FDA approval. The development history is relevant because it explains why ipamorelin has substantial human safety data despite never having a marketed indication.

Compounding-clinic adoption

Following the closure of the postoperative-ileus pathway, ipamorelin remained on the radar of GH-axis clinicians and entered US 503A compounding practice as part of the broader GHRP/GHRH category. It is most commonly prescribed in combination with CJC-1295, an approach described in clinical reviews of GH secretagogue combinations (Sigalos and Pastuszak, 2018).

Comparative GHRP literature

Comparative pharmacology studies of GHRP-2, GHRP-6, hexarelin, and ipamorelin (summarized in reviews by Smith et al. in Endocrine Reviews on GH secretagogues) consistently identify ipamorelin as the most selective member of the class. Older agents produced cortisol and prolactin elevations that complicated long-term use; ipamorelin’s selectivity is the reason it persisted in clinical practice while several earlier GHRPs were largely abandoned.

Administration (research context).

In the published trials and in current 503A compounding practice, ipamorelin is administered by subcutaneous injection. It has a short plasma half-life (roughly two hours), so dosing is timed to mimic the natural pulsatile pattern of GH release, often before sleep when endogenous GH output is highest.

When ipamorelin is paired with a GHRH analog (CJC-1295 with or without DAC, or sermorelin), the two agents are typically combined in a single injection because they engage complementary receptors on the same somatotrope population. There is no FDA-approved dosing standard for ipamorelin in any indication; clinical protocols vary by prescriber.

This is research context, not prescribing guidance. Ipamorelin is handled consultation-first. Any decision about a GH-axis protocol belongs in a clinician-led consultation.

Side effects & safety considerations.

Drawn from the published Phase 2 dataset and the broader GH secretagogue literature.

Reported side effects

  • Injection-site reactions (redness, mild swelling, transient itching)
  • Mild fluid retention
  • Increased hunger (consistent with ghrelin-receptor agonism)
  • Headache, generally mild and transient
  • Occasional fatigue or post-dose drowsiness

Monitoring considerations

Because ipamorelin elevates GH pulses and downstream IGF-1, prescribers monitor IGF-1 over time to keep levels within an age-appropriate range. Sustained supraphysiologic IGF-1 elevation is the safety concern that drives the long-term monitoring requirement for all GH-axis interventions, GH secretagogues included. Patients with active malignancy, uncontrolled diabetes, severe insulin resistance, or proliferative retinopathy are generally considered unsuitable for GH-axis therapy.

Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.

Legal status.

Ipamorelin is not an FDA-approved drug for any indication. The Helsinn postoperative-ileus development program reached Phase 2 but did not result in marketing approval, and no other sponsor has carried ipamorelin through an NDA pathway since.

Following the FDA’s April 15, 2026 actions on the Section 503A bulk substances list, ipamorelin sits in regulatory ambiguity alongside several other GH secretagogues and ghrelin-pathway peptides. It has been treated as a Category-1-ambiguous substance pending PCAC review, with the reviews expected in mid-2026 through early 2027. PepScribe’s internal posture is to default to consultation-first treatment until the regulatory status is unambiguously resolved.

Compounding by licensed 503A pharmacies is currently being conducted under the “removal lifts prohibition” theory, but the legal certainty that applies to FDA-approved drugs (or to peptides on the formal Category 1 list) does not yet apply here. Gray-market vials labeled as ipamorelin and sold for “research use only” carry no pharmaceutical-grade quality assurance and are outside any clinician-supervised pathway.

Deep dives

More on Ipamorelin.

Research-backed articles covering specific topics in depth.

References

  1. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH) (1998).
  2. The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulation. International Journal of Molecular Sciences (Yin Y, Li Y, Zhang W) (2014).
  3. Integrating GHS into the Ghrelin System. International Journal of Peptides (Veldhuis JD, Bowers CY) (2010).
  4. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration (FDA) (2025).

What Reddit says

r/Biohackers122 points235 commentsFeb 2026

2 Months on CJC-1295 (No DAC) + Ipamorelin: The strength gains are real.

Eight weeks at 100 micrograms each of ipamorelin and CJC-1295 without DAC, taken nightly on a five-days-on schedule and two hours fasted, produced what the poster called real strength gains starting around week four. The replies did the checking the post did not: one commenter tested first and found IGF-1 already above range, and another who ran the identical stack reported the same recomposition but worse sleep, the reverse of what growth hormone secretagogues are usually credited with.

Posted on Reddit

Explore clinician-led GH-axis options.

Ipamorelin sits in the FDA regulatory ambiguity and is consultation-first only. Take the assessment to see which legal, clinician-prescribed options match your goals.

Explore the Longevity programBack to The Peptide Library

Written by B.A. Utterback.

Educational information only. Not medical advice. Treatment decisions are made by a licensed physician.